Schneider lab
The Schneider group studies the bacterial cell envelope as a target for (new) antibiotics. Much of our current research focuses on the elucidation of molecular mechanisms of action and resistance of (new) antibiotics and the identification & characterization of novel antibacterial targets. Pivotal to these efforts is to understand the biology beyond a given target as well as its integration into the cellular network.
Current research interests:
- Mode of action studies on novel antibiotics (e.g. teixobactin, plectasin, lipopeptides)
- Antibiotic resistance mechanisms
- Identification of new antibiotic targets and screening
- Investigations on cell envelope biosynthesis in S. aureus, particularly peptidoglycan, wall teichoic acid and capsule biosynthesis
- Regulation of cell envelope biosynthesis and modification
Group Leader/ Head of Department
Tanja Schneider studied biology in Bonn, Germany, specialized in microbiology and obtained her PhD in 2004. Following a postdoctoral training at the Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, she joined industry from 2011 until 2012. During that time she worked at the Peptide and Cell Discovery Department at Novozymes A/S, Denmark in the course of a Marie Curie Actions fellowship. Returning to Germany, she became a junior research group leader within the German Center for Infection Research (DZIF). In 2014 she completed her habilitation in Medical-Pharmaceutical Microbiology and was appointed Professor of Pharmaceutical Microbiology at the University of Bonn in 2015.
